Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Comment by Islandcron Aug 22, 2018 1:37am
130 Views
Post# 28497227

RE:RE:RE:RE:News on the docket

RE:RE:RE:RE:News on the docketThe warrants that are set to expire Sept 16th (3.75m) @.075 and Oct 19th (1.785m) @.10 if all exercised is worth $460k not exactly big money and no guarantee, although they should, all get exercised. Obviously not in dire need but more so to the point of what will they do with the capital they have as it's going to take significantly more money to ramp things up (retail and license activity) and be successful while going it alone if that continues to be the plan. Even a minor involvement from a bigger player pushes this into a share price where raising money will be minorly dilutive to the float while giving us enough capital to get rolling, that's if they are able to pull something like that off even if they have significant industry connections.

Good points about the pet treatments Ten I just wasn't sure if they would be able to sling out some treatment after only one pet trial. If that's a possibility then hopefully they can move on that market asap.
<< Previous
Bullboard Posts
Next >>